PHAT_OUT_1 [2025-04-04 05:01:22 -0400] 2710 Bytes | 736 tokens | Cum: 736 tkns (9.20% of 8k)
==========================================================================

We're scouting for winners today. Its 5:01:21 AM on Fri Apr 04, 2025 -0400 and I'm looking at Phathom Pharmaceuticals (PHAT) up to 6.78 from 5.005

Help me investigate to see if its got potential or just another dud. So, I pulled together a bunch of data for you to look over real fast.

--- COMPANY PROFILE ---
Company: Phathom Pharmaceuticals (PHAT)
IPO: IPO date unknown
Shares Outstanding: 69,640,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS

Here’s the first list of news for Phathom Pharmaceuticals:

C1 - Apr-03-25 11:25AM - Phathom Pharmaceuticals: The Clock Is Ticking On Voquezna (Downgrade)
C2 - Apr-03-25 11:25AM 08:00AM - Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
C3 - Apr-01-25 04:15PM - Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
C4 - Apr-01-25 04:15PM 08:00AM - Phathom Pharmaceuticals Announces Leadership Succession
C5 - Mar-31-25 07:59AM - Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA (vonoprazan)
C6 - Mar-07-25 02:08AM - Phathom Pharmaceuticals Inc (PHAT) Q4 2024 Earnings Call Highlights: FDA Approval Boosts ...
C7 - Mar-06-25 09:10AM - Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates
C8 - Mar-06-25 09:10AM 08:00AM - Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Prior AI Reports for PHAT:
1. 2025-04-02 – Score: 40 – Target: 6.7300 – Highs: 6.2600 / 5.4781 / –
impressive-sales-growth-amid-financial-instability-and-high-short-interest

(Note: Highs = Same day / 2nd day / 3rd day)

GUIDELINES FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and reporting system.
Your role is to examine all available company data and draw sound conclusions.

2) To request additional information, refer to any listed documents using their reference codes.
The company under analysis is: Phathom Pharmaceuticals (PHAT).

3) As the analysis proceeds, continue reviewing documents until you feel confident in your judgment.
When ready, you will:
- Write a brief summary
- Generate a headline
- Assign a MARKET_SCORE[XX]
- Set a PRICE_TARGET[XX]

4) For now, restrict your response to just **three tokens**.
To request a document, reply with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

PHAT_OUT_3 [2025-04-04 05:01:26 -0400] 724 Bytes | 219 tokens | Cum: 958 tkns (11.97% of 8k)
==========================================================================

Showing C1 (chunk 1 of 1): C1:
**Phathom Pharmaceuticals: The Clock Is Ticking On Voquezna (Downgrade)**
Date: Apr-03-25 11:25AM
Source: (Seeking Alpha)
URL: https://seekingalpha.com/article/4772792-phathom-pharmaceuticals-clock-ticking-on-voquezna-downgrade?utm_source=finviz.com&utm_medium=referral&feed_item_type=article

Error fetching article: 403 Client Error: Forbidden for url: https://seekingalpha.com/article/4772792-phathom-pharmaceuticals-clock-ticking-on-voquezna-downgrade?utm_source=finviz.com&utm_medium=referral&feed_item_type=article

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PHAT_OUT_5 [2025-04-04 05:01:26 -0400] 1015 Bytes | 286 tokens | Cum: 1314 tkns (16.43% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-03T12:25:33Z - Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference By Inves...
A2 - 2025-04-03T12:00:25Z - Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference - Phatho...
A3 - 2025-04-01T20:17:03Z - Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...
A4 - 2025-04-01T20:32:45Z - Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Taiwan Ne...
A5 - 2025-04-01T20:27:23Z - Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

PHAT_OUT_7 [2025-04-04 05:01:31 -0400] 1098 Bytes | 304 tokens | Cum: 1620 tkns (20.25% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference By Investing.com**Date: 2025-04-03Source: {'uri': 'investing.com', 'dataType': 'news', 'title': 'Investing.com'}URL: https://www.investing.com/news/press-releases/phathom-pharmaceuticals-to-present-at-the-24th-annual-needham-virtual-healthcare-conference-93CH-3965048FLORHAM PARK, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of the management team will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8th, 2025, at 10:15 am ET.

Company management will also participate in one-on-one meetings during the conference, which will run from April 7-10, 2

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PHAT_OUT_9 [2025-04-04 05:01:32 -0400] 963 Bytes | 275 tokens | Cum: 1986 tkns (24.82% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-04-01T12:00:00Z - Phathom Pharmaceuticals Announces Leadership Succession
B2 - 2025-03-06T13:00:00Z - Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
B3 - 2025-01-29T13:00:00Z - Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference
B4 - 2024-10-28T12:00:00Z - Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024
B5 - 2024-08-21T19:16:00Z - The Top 3 Most-Shorted Stocks in August
B6 - 2024-08-08T12:00:00Z - Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PHAT_OUT_11 [2025-04-04 05:01:34 -0400] 761 Bytes | 203 tokens | Cum: 2191 tkns (27.39% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/01/29/3017141/0/en/Phathom-Pharmaceuticals-to-Present-at-the-Guggenheim-Securities-SMID-Cap-Biotech-Conference.htmlPhathom Pharmaceuticals, a biopharmaceutical company focused on gastrointestinal diseases, announced that members of its management team will participate in a fireside chat and one-on-one meetings at the Guggenheim Securities SMID Cap Biotech Conference.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PHAT_OUT_13 [2025-04-04 05:01:35 -0400] 1086 Bytes | 256 tokens | Cum: 2496 tkns (31.20% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S4 - 2025-03-06 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes included elsewhere ...

S5 - 2025-03-06 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes included elsewhere ...

S6 - 2025-03-06 8-K Item2.02 Results of Oper and Fin Cond.

On March 6, 2025, Phathom Pharmaceuticals, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and i...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PHAT_OUT_15 [2025-04-04 05:01:35 -0400] 1098 Bytes | 231 tokens | Cum: 2729 tkns (34.11% of 8k)
==========================================================================

Showing S4 (chunk 1 of 6): S4:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes included elsewhere in this annual report. This discussion and analysis contains forward-looking statements based upon our current beliefs, plans and expectations that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under Risk Factors or in other parts of this annual report.

Overview

We are a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Our approved products, VOQUEZNA, VOQUEZNA TRIPLE PAK and VO

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PHAT_OUT_17 [2025-04-04 05:01:36 -0400] 1098 Bytes | 270 tokens | Cum: 3001 tkns (37.51% of 8k)
==========================================================================

Showing S4 (chunk 2 of 6): QUEZNA DUAL PAK, contain vonoprazan, an oral small molecule potassium-competitive acid blocker, or PCAB. PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan is the first gastric anti-secretory agent from a novel class approved in the United States, Europe, or Canada in over 30 years, and has shown rapid, potent, and durable anti-secretory effects. Vonoprazan has also demonstrated clinical benefits over the current standard of care as a single agent in the treatment of erosive gastroesophageal reflux disease, or Erosive GERD, and in combination with antibiotics for the treatment of Helicobacter pylori , or H. pylori , infection. Takeda Pharmaceutical Company Limited, or Takeda, developed vonoprazan and has received marketing approval in numerous countries in Asia and Latin America as well as Russia. Vonoprazan generated peak net sales of approximately

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PHAT_OUT_19 [2025-04-04 05:01:49 -0400] 5823 Bytes | 1624 tokens | Cum: 4627 tkns (57.84% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+-------------------------+-------------------------+
| Volume: 1,232,257 | Perf Month: -17.68% | Option/Short: Yes / Yes | Sales Y/Y TTM: 8001.47% |
+--------------------+-----------------------+-------------------------+-------------------------+
| Avg Volume: 1.20M | Perf Quarter: -38.36% | Short Float: 37.16% | ROE: - |
+--------------------+-----------------------+-------------------------+-------------------------+
| Rel Volume: 1.03 | Index: RUT | Short Ratio: 12.01 | ROI: -118.94% |
+--------------------+-----------------------+-------------------------+-------------------------+
| RSI (14): 41.87 | Market Cap: 348.53M | Short Interest: 14.36M | Sales Surprise: 18.99% |
+--------------------+-----------------------+-------------------------+-------------------------+
| ATR (14): 0.66 | Shs Outstand: 68.52M | Beta: 0.11 | EPS Surprise: 13.58% |
+--------------------+-----------------------+-------------------------+-------------------------+
| SMA20: -10.12% | Shs Float: 38.63M | Sales Q/Q: 4249.56% | P/E: - |
+--------------------+-----------------------+-------------------------+-------------------------+
| SMA50: -13.07% | Inst Own: 60.24% | Sales past 5Y: 1600.29% | Earnings: Mar 06 BMO |
+--------------------+-----------------------+-------------------------+-------------------------+
| SMA200: -53.77% | Insider Own: 44.53% | Employees: 427 | |
+--------------------+-----------------------+-------------------------+-------------------------+
| Perf Week: -25.19% | Insider Trans: -0.01% | Debt/Eq: - | |
+--------------------+-----------------------+-------------------------+-------------------------+

The next section covers any insider trading if any are accessible.

Inside Trans: Phathom Pharmaceuticals, Inc. (PHAT) by Basta Steven L (President and CEO) on 2025-04-03
- Performance Shares: 360000 shares at $0 (D)
- Stock Option (Right to Buy): 1085000 shares at $0 (D)

No transactions recorded.

Inside Trans: Phathom Pharmaceuticals, Inc. (PHAT) by Parikh Asit (Unknown Title) on 2025-03-13
- Common Stock: 10000 shares at $4.42 (D)

Inside Trans: Phathom Pharmaceuticals, Inc. (PHAT) by Henderson Molly (CFO and CBO) on 2025-02-27
- Common Stock: 72000 shares at $0 (D)
- Stock Option (Right to Buy): 50000 shares at $0 (D)

Inside Trans: Phathom Pharmaceuticals, Inc. (PHAT) by Nabulsi Azmi (Chief Operating Officer) on 2025-02-27
- Common Stock: 79200 shares at $0 (D)
- Stock Option (Right to Buy): 55000 shares at $0 (D)

Inside Trans: Phathom Pharmaceuticals, Inc. (PHAT) by Curran Terrie (President and Chief Executive) on 2025-02-27
- Stock Option (Right to Buy): 342500 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 55252000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -334326000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 5.005
Average Volume: 1565996.59
30-Day High: 6.69
30-Day Low: 4.22

[Detailed Financials: TTM 2024]
- Total Assets: $378,318,000.0
- Total Liabilities: $631,898,000.0
- Total Equity: $-253,580,000.0
- Current Assets: $360,134,000.0
- Current Liabilities: $85,728,000.0

[Income Statement: TTM 2024]
- Revenue: $55,252,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -5.29

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-84,131,000.0

[Detailed Financials: FY 2024]
- Total Assets: $378,318,000.0
- Total Liabilities: $631,898,000.0
- Total Equity: $-253,580,000.0
- Current Assets: $360,134,000.0
- Current Liabilities: $85,728,000.0

[Income Statement: FY 2024]
- Revenue: $55,252,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -5.29

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-84,131,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Do not say you lacked information. Save that for the final survey.

Now complete this report with the following:

1) Brief Summary: Explain your findings in one well-worded paragraph.

2) MARKET_SCORE: Estimate a number between 1 and 100 to represent the likelihood of an upward price move over the next day, week, or longer. Use the format: MARKET_SCORE[XX]
Weigh all relevant data —- news, SEC filings, fundamentals, and metrics —- and assign each element appropriate weight to calculate a general MARKET_SCORE[XX].
This score should be grounded in objective reasoning and guided by your analytical judgment.
XX must be a whole number between 1 and 100.

3) PRICE_TARGET: The current price of {ticker} is {current_price}.
If you believe it’s likely to rise, calculate a reasonable new price target.
For example, if you expect a 50% increase, say: PRICE_TARGET[{increased_price}]
You are encouraged to reference prior price performance when making this estimate.

4) AI_RPT_HEADLINE: Provide a thought-provoking headline (8–12 words) summarizing the situation.
Examples:
- AI_RPT_HEADLINE[{co_name} makes news with FDA approval fueling high investor optimism]
- AI_RPT_HEADLINE[Declining sales plague {ticker}, worsening an already negative outlook]

Return only:
1) Brief Summary
2) MARKET_SCORE[]
3) PRICE_TARGET[]
4) AI_RPT_HEADLINE[]

PHAT_OUT_21 [2025-04-04 05:01:51 -0400] 687 Bytes | 169 tokens | Cum: 5110 tkns (63.88% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More news listings
-> X2 <- More SEC filing extractions (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider trading extractions (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this company
-> X8 <- Something altogether different (explain...)

PHAT_IN_23 [2025-04-04 05:01:52 -0400] 126 Bytes | 29 tokens | Cum: 5205 tkns (65.06% of 8k)
==========================================================================

====================================
[2025-04-04 05:01:52] # Analysis Completed
Elapsed Time: 30.38 seconds